Whole Genome and Exome Sequencing Market Report 2026

The whole genome and exome sequencing market size has grown exponentially in recent years. It will grow from $2.52 billion in 2025 to $3.14 billion in 2026 at a compound annual growth rate (CAGR) of 24.8%. The growth in the historic period can be attributed to advancements in next-generation sequencing technologies, increasing use of genomics in cancer research, expansion of academic genomics initiatives, declining sequencing costs, growth of precision medicine programs.

The whole genome and exome sequencing market size is expected to see exponential growth in the next few years. It will grow to $7.63 billion in 2030 at a compound annual growth rate (CAGR) of 24.8%. The growth in the forecast period can be attributed to increasing deployment of large-scale genomics projects, rising integration of ai in genomic analysis, expansion of clinical genomics adoption, growing investments in sequencing infrastructure, increasing demand for personalized treatment strategies. Major trends in the forecast period include increasing adoption of comprehensive genome sequencing, rising use of sequencing in oncology diagnostics, growing demand for integrated wgs and wes workflows, expansion of population genomics studies, enhanced focus on high-throughput sequencing platforms.

The increasing demand for personalized medicine is expected to drive the growth of the whole genome and exome sequencing market in the coming years. Personalized medicine is an approach to healthcare that customizes treatment and medical decisions based on an individual’s unique characteristics, including genetics, environment, and lifestyle. Whole genome and exome sequencing supports personalized medicine by providing a comprehensive analysis of an individual’s genetic makeup, enabling healthcare decisions and interventions tailored to their specific genetic, environmental, and lifestyle factors. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based organization promoting personalized medicine, the FDA approved 26 personalized medicines in 2023, including 20 new molecular entities (NMEs) and six gene- or cell-based therapies, representing approximately 38% of all newly approved therapeutic NMEs. Therefore, the growing demand for personalized medicine is driving growth in the whole genome and exome sequencing market.

Leading companies in the whole genome and exome sequencing market are focusing on developing advanced technological solutions, such as ultra-fast NGS (next-generation sequencing) analysis, to maintain a competitive edge. Ultra-fast NGS analysis is a technological advancement that allows next-generation sequencing data to be processed at exceptionally high speeds, significantly reducing the time needed for genomic analysis. For instance, in January 2023, QIAGEN Digital Insights (QDI), a US-based bioinformatics company, launched an ultra-fast NGS analysis platform. This platform can process a whole genome in 25 minutes at a cloud computing cost of $1, enhancing efficiency, affordability, and scalability. Its innovation greatly improves the speed and accessibility of genomic analysis, supporting rapid decision-making and broader adoption of personalized medicine.

In January 2023, QIAGEN, a Germany-based global provider of molecular insights and sample technologies, acquired Verogen for an undisclosed amount. This acquisition strengthens QIAGEN’s capabilities in the human identification and forensics market, reinforcing its leadership and enabling the development of more comprehensive solutions with potential implications for the whole genome and exome sequencing market. Verogen is a US-based biotechnology company offering NGS tools and services, including whole genome and exome sequencing.

Major companies operating in the whole genome and exome sequencing market are Siemens AG, Hoffmann‑La Roche Ltd., Thermo Fisher Scientific Inc., Cytiva (Danaher Corporation), Laboratory Corporation of America Holdings, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V, BGI Genomics, Novogene Co., Oxford Nanopore Technologies Inc., Pacific Biosciences of California Inc., GENEWIZ Inc., 10x Genomics Inc., MGI Tech Co. Ltd., Clear Labs Inc., Macrogen Inc., PierianDx Inc., Invitae Corporation, Fulgent Genetics Inc., SOPHiA GENETICS SA, Azenta US Inc., Gene by Gene Ltd.

North America was the largest region in the whole genome and exome sequencing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the whole genome and exome sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the whole genome and exome sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the whole genome and exome sequencing market by increasing costs of imported sequencing instruments, reagents, consumables, and advanced data analysis systems. Research centers and hospitals in North America and Europe are most affected due to reliance on imported high-throughput sequencing platforms, while Asia-Pacific faces cost pressure on instrument manufacturing and exports. These tariffs are raising capital investment requirements and slowing technology upgrades. However, they are also encouraging domestic instrument assembly, regional reagent production, and localized genomic service ecosystems.

The whole genome and exome sequencing market research report is one of a series of new reports that provides whole genome and exome sequencing market statistics, including whole genome and exome sequencing industry global market size, regional shares, competitors with a whole genome and exome sequencing market share, detailed whole genome and exome sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the whole genome and exome sequencing industry. This whole genome and exome sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Whole genome sequencing (WGS) and exome sequencing (ES) are comprehensive genetic analysis techniques that involve determining the complete DNA sequence of an organism’s genome and sequencing the protein-coding regions. These techniques are used to analyze a person’s DNA for diagnosing genetic diseases and detecting cancer-related mutations.

The primary types of products included in whole genome and exome sequencing are kits and instruments. A kit is a collection of separate but related products packaged together to simplify inventory management and tracking. The workflows include whole genome sequencing (WGS) and whole exome sequencing (WES), which are applied across various areas such as diagnostics, cancer, monogenic disorders, diabetes, drug discovery and development, personalized medicine, agriculture, and animal research. The end users include research centers, academic and government institutions, hospitals and clinics, pharmaceutical and biotechnology companies, and others.

The whole genome and exome sequencing market consists of revenues earned by entities by providing services such as genetic profiling, variant identification, personalized medicine solutions, and comprehensive genomic analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The whole genome and exome sequencing market also includes sales of exome capture kits, benchtop sequencer, and sample preparation instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.